KUALA LUMPUR: CIMB Equities Research has started coverage of Hovid with an Outperform call and a target price of 43 sen, based on sum-of-parts valuation.
It said on Wednesday the re-rating catalysts could come from increased product registrations in its export markets and strong earnings growth.
